Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRemoved related topics: 'Bladder cancer' and 'MedlinePlus Genetics' from the page's related topics section. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check19 days agoChange DetectedPage version updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check26 days agoChange DetectedThe top government funding status notice was removed; the study details, contacts, locations, and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check49 days agoChange DetectedNo significant changes detected in the study details page between versions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%
- Check70 days agoChange DetectedThe page has been updated to include a government-status notice and a version upgrade to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
- Check77 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.